Neurology: Disease Deep Dive

In this episode, Patrick J. Strollo Jr, MD, FACP, FCCP, FAASM, of the University of Pittsburgh Department of Medicine, Pittsburgh, PA, discusses the data from the phase 3 SynAIRgy clinical trial for AD109, an investigational once-nightly oral treatment targeting neuromuscular dysfunction in obstructive sleep apnea, and its potential role in a more personalized approach to OSA care.

This episode explores the real-world implementation of the Davos Alzheimer’s Collaborative Healthcare System Preparedness (DAC-SP) US Early Detection Program at Virtua Health, examining outcomes in identifying cognitive impairment, streamlining referrals, and supporting efficient use of clinical resources. Elyse Perweiler, RN, MPP, Professor, Rowan–Virtua School of Osteopathic Medicine, Stratford, NJ, and Tim MacLeod, PhD, Executive Director, Healthcare System Preparedness Program, DAC, Toronto, Ontario, Canada, return for part 2 of this 3 part series.

Elyse Perweiler, RN, MPP, Professor, Rowan–Virtua School of Osteopathic Medicine, Stratford, NJ, and Tim MacLeod, PhD, Program Director, Healthcare System Preparedness Program, Davos Alzheimer’s Collaborative (DAC), Toronto, Ontario, Canada, examine how health systems can operationalize early cognitive screening to better prepare patients for specialty evaluation. Learn how standardized workflows, digital cognitive tools, and primary care–neurology collaboration can enhance diagnostic efficiency and access to Alzheimer disease care.

This episode explores new evidence showing that paramagnetic rim lesions (PRLs) are highly prevalent early in multiple sclerosis (MS) and can differentiate MS from mimics with striking accuracy. Dr. Daniel Ontaneda, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, and Dr. Pascal Sati, Cedars-Sinai Medical Center,  Los Angeles, CA, discuss how PRLs, paired with optimized susceptibility-based MRI, are reshaping diagnostic confidence and informing the latest revisions to the McDonald criteria.

Patrick Y. Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current standards of care for low- and high-grade gliomas, including the importance of comprehensive molecular testing, the World Health Organization classification of tumors of the central nervous system, and newly available therapies.